Bloomberg Open Interest 05/01/2025
Strong tech earnings set the stage for an eighth straight day. GM slashes its guidance with up to a $5 billion dollar hit from tariffs; Kohl's fires its CEO who's been on the job for less than 5 months; Eli Lilly falls after CVS announced a plan to drop its blockbuster weight-loss drug Zepbound, making rival Wegovy more widely available. We talk AI Infrastructure with Marc Ganzi, the CEO of DigitalBridge. Vlad Tenev, Robinhood CEO is in the C-Suite talking cryptocurrencies and the company's strong earnings. (Source: Bloomberg)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Eli Lilly's obesity drug sales rise in India, Bloomberg reports
Eli Lilly (LLY) increased its sale of Mounjaro, its weight-loss and diabetes drug, by 60% in India in May from April, Satviki Sanjay of Bloomberg reports. The company sold $1.5M worth of injections last month, Bloomberg said, citing market analysis firm Pharmarack Technologies. 'The patient number may have actually doubled' in May from April Pharmarack Vice President Sheetal Sapale told Bloomberg News. The demand is rising gradually and is expected to continue. Confident Investing Starts Here:
Yahoo
a day ago
- Yahoo
Billionaire Stanley Druckenmiller Has Unloaded Shares of Last Year's 2 Top Performing AI Stocks and Is Piling Into a Growth Stock That Has Climbed 150% in 3 Years
Druckenmiller has a stunning investment track record, regularly delivering double-digit percentage annual returns with no money-losing years. In recent times, the billionaire has benefited from investments in some of today's top growth stocks. 10 stocks we like better than Eli Lilly › You don't have to be a billionaire to invest like one -- and reap the rewards. Any of us can look at the moves made by the world's most successful investors and follow those that also fit into our investment strategy. Billionaire fund managers have proven their strengths as investors over time, making them excellent guides for novices on the wealth-building path. With that in mind, let's consider the recent moves made by Stanley Druckenmiller, founder of the Duquesne Family Office. Over the past few quarters, he closed his position in last year's two top-performing S&P 500 and Dow Jones Industrial Average artificial intelligence (AI) stocks, and just recently, he increased his position in a growth stock that has soared by 150% over the past three years. Could taking those cues be a smart move for you? So, first, a bit about why Druckenmiller is a billionaire worth watching and potentially following. He founded Duquesne Capital Management in the early 1980s and ran the fund for 30 years. Over that time period, he delivered a truly remarkable annualized average return of 30% -- and importantly, never had a money-losing year. Since then, he has shifted his focus to his family office, where he invests in stocks across industries and oversees $3 billion in securities. Now, let's consider his recent moves, starting with a major one. In the third quarter, Druckenmiller closed out his position in AI chip market leader Nvidia (NASDAQ: NVDA), a company that climbed a bit further from there, becoming the Dow Jones Industrial Average component that delivered the biggest annual gain of 2024. The investor originally bought Nvidia shares in the fourth quarter of 2022, and from the end of that quarter through the end of last year's third quarter, they climbed by more than 700%. So this clearly was a winning investment for Druckenmiller, though in a Bloomberg interview, he expressed regret about the timing of the sale, and said he would consider buying Nvidia stock again at the right price. Druckenmiller's second big sale came in the first quarter of this year: He closed out his position in Palantir Technologies (NASDAQ: PLTR), a stock he bought a year earlier. Last year, the AI software company generated the biggest gain in the S&P 500, climbing by 340%. Meanwhile, Druckenmiller increased his position in another growth stock: pharma giant Eli Lilly (NYSE: LLY), which in recent quarters has delivered double-digit percentage revenue gains. That growth came largely thanks to its position in a high-growth market with solid long-term potential: weight loss drugs. Druckenmiller increased his Lilly holding by 52% in the first quarter and now owns 94,830 shares worth about $73 million as of the close of trading Friday. Lilly represents nearly 2.6% of the billionaire's portfolio, up from about 1.3% in the previous quarter. He initially bought the stock in 2024's fourth quarter, so he clearly is building a position in it, and sees opportunity for growth ahead. Lilly sells a wide variety of medicines, but investors have focused on its GLP-1 agonist tirzepatide in recent quarters -- and for good reason. Tirzepatide is sold under the name Mounjaro for type 2 diabetes and Zepbound for weight loss, and both drugs are generating blockbuster revenues. Doctors have prescribed either one for weight loss, and demand has been so high that last year, both were on the Food and Drug Administration's shortage list. These drugs should continue to generate sales growth due to ongoing high demand; analysts at Goldman Sachs forecast that the weight loss drug market will be about $95 billion annually by 2030. One more element may supercharge Lilly's growth in this market. Mounjaro, Zepbound, and the competing GLP-1 drugs on the market today all must be administered via injection, but Lilly has been developing a new weight loss candidate in pill form. Phase 3 trials have produced strong data for the pill, dubbed orforglipron, and Lilly says it will apply for regulatory review in the weight loss indication by the end of this year. The convenience of a weight loss pill that is as effective as the injectables could help orforglipron (and Lilly) take a leading share of the market in the years to come. So the drugmaker's growth may be far from over. Should you follow Druckenmiller's lead, exit Nvidia and Palantir (if you own them), and get in on Lilly shares? All three of these companies are leaders in exciting growth markets and could gain over the long term, so your decisions should depend on your investment strategy. If you're a cautious investor and like passive income, Eli Lilly is a great choice to own because, while it does offer share price growth potential, it also offers the safety and steady dividends of an established pharma player. If you're an aggressive investor, though, you may want to favor the AI story and continue along with Nvidia and/or Palantir over the long term. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia and Palantir Technologies. The Motley Fool has a disclosure policy. Billionaire Stanley Druckenmiller Has Unloaded Shares of Last Year's 2 Top Performing AI Stocks and Is Piling Into a Growth Stock That Has Climbed 150% in 3 Years was originally published by The Motley Fool
Yahoo
a day ago
- Yahoo
Road near bottlenecked I-77 Lake Norman exit to close for highway widening
Crews will temporarily close a road near a Lake Norman-area retail center anchored by Belk, Kohl's and Big Lots for the $249 million N.C. 150 widening project, state highway officials said Friday. Portestowne Way in Mooresville will be closed 8 a.m.-4 p.m. Monday, June 9, through Thursday, June 12, so crews can safely install a storm drain at the N.C. 150 intersection, according to the N.C. Department of Transportation. That's just east of Interstate 77 exit 36. Drivers will be detoured from Portestowne Way to Forester Street and Corporate Center Drive, and back onto N.C. 150. Crews plan to widen 15 miles of N.C. 150 from just west of the U.S. 21/N.C. 150 interchange in Mooresville to N.C. 16 Bypass in Catawba County. A 5.5-mile stretch from Greenwood Road in Terrell on the lake to U.S. 21 in Mooresville is under construction. Charlotte-based contractor Blythe Development LLC is expanding the highway from four to six lanes, officials said. Part of the stretch includes the old two-lane bridge over the lake. An additional bridge will carry westbound traffic, from Mooresville into Catawba County. Improvements to the bottlenecked I-77/N.C. 150 exit 36 interchange are planned.
